Sanofi said to weigh alternative deals to Medivation; eyes BioMarin Pharmaceutical - sources

French pharmaceutical giant Sanofi is working on a back up plan in case it fails to win its $9.3 billion hostile pursuit of US-listed Medivation.

Top sources have told me the French pharmaceutical giant has begun looking at US-based rare disease specialist BioMarin Pharmaceutical as a potential alternative takeover deal after growing frustrated in its pursuit of Medivation, which has so far resisted the French company's advances...

Register

Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Friday, 17 June 2016, 12:00 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation